Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Latest

    Chinese vaccine proves 79.34 pct effective against COVID-19 in phase-3 study

    Xinhua | Updated: 2020-12-30 17:59
    Share
    Share - WeChat
    A coronavirus disease (COVID-19) Human Immunoglobulin for Intravenous Injection from China National Biotec Group (CNBG). [Photo/Agencies]

    BEIJING - A Chinese inactivated vaccine shows 79.34 percent efficacy against COVID-19, according to the interim results of the phase-3 clinical trials unveiled by its developer Wednesday.

    The inactivated vaccine is developed by the Beijing Biological Products Institute Co Ltd under the China National Biotec Group, which is affiliated with Sinopharm.

    After a two-dose inoculation procedure, the vaccine receivers all produced high titers of antibodies, and the seroconversion rate of neutralizing antibodies reached 99.52 percent.

    The results meet the requirements of technical standards of the World Health Organization and the standards stipulated by China's National Medical Products Administration.

    The company has submitted an application to the NMPA for conditioned market approval.

    China has adopted five technological approaches in developing COVID-19 vaccines, with 15 vaccines entering clinical trials, of which five are undergoing phase-3 clinical trials.

    To protect high-risk groups, China approved the emergency use of COVID-19 vaccines in June. China has already conducted nearly 1 million emergency inoculations, which were given on a voluntary, informed basis and in accordance with relevant laws and regulations.

    Inactivated vaccines for emergency use include two inactivated vaccines developed by the CNBG and one by Sinovac Biotech. They have all entered international phase-3 clinical trials.

    About 75,000 people overseas have been enrolled in the phase-3 trials of the three vaccines, with 150,000 doses inoculated. "Study results have shown no serious safety threats," Zheng Zhongwei, an official with the National Health Commission, said in a press conference earlier this month.

    Some of the Chinese vaccine developers have just obtained enough samples for the interim analysis of phase-3 clinical trials and are submitting related materials to the NMPA, Zheng has said, adding that only vaccines meeting certain standards will be allowed to enter the market.

    Next, with COVID-19 vaccines officially approved to enter the market or the yield of vaccines improving steadily, China will put more vaccines into use, inoculating the eligible population as widely as possible, Cui Gang, an official with NHC's disease control department, has said.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    一本加勒比hezyo无码专区| 国产成人AV无码精品| 无码人妻丰满熟妇啪啪| 中文字幕日韩精品有码视频| 99久久精品无码一区二区毛片| 免费无码国产在线观国内自拍中文字幕 | 佐藤遥希在线播放一二区| 亚洲AV无码专区国产乱码4SE| 久久精品aⅴ无码中文字字幕不卡| 免费无码毛片一区二区APP| AV无码久久久久不卡蜜桃 | 亚洲日韩AV一区二区三区中文| 亚洲Av无码国产情品久久| 久久久无码一区二区三区| 国产成人麻豆亚洲综合无码精品| 波多野结衣在线中文| 无码人妻精品一区二区三区99不卡| 亚洲AV无码码潮喷在线观看| 亚洲欧洲中文日韩av乱码| 久久久久中文字幕| 亚洲中文字幕在线观看| 亚洲欧美精品一中文字幕| 18禁免费无码无遮挡不卡网站| 日韩精品无码久久久久久| 亚洲国产精品无码久久98| 中文字幕av无码专区第一页| 最近中文字幕免费大全| 最近免费中文字幕mv电影| 欧美中文在线视频| 最近高清中文字幕免费| 91中文在线观看| 亚洲日本中文字幕天堂网| 日韩人妻无码精品系列| 最近最新中文字幕视频| 免费无码又爽又刺激网站| 亚洲精品无码MV在线观看 | 亚洲中文久久精品无码ww16| 中文无码字慕在线观看| 在线播放无码后入内射少妇| 精品无码国产自产在线观看水浒传| 合区精品中文字幕|